
Meera B Chitlur MD
Pediatric Coagulation Disorder Hematology
Professor, Pediatrics, Wayne State University School of Medicine
Join to View Full Profile
3901 Beaubien StDetroit, MI 48201
Phone+1 313-745-5515
Fax+1 313-745-5432
Dr. Chitlur is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Meera Chitlur is the Professor of Pediatrics at Central Michigan University and Barnhart-Lusher Hemostasis Research Endowed Chair at Wayne State University. She is the Director of the Hemophilia Treatment Center and the Jeanne M. Lusher Special Coagulation laboratory at Children’s Hospital of Michigan. Dr.Chitlur is the PI of a multicenter study evaluating the safety of high intensity sports in Hemophilia A patients on Emicizumab vs FVIII replacement (STeP study), Co-PI of the Glanzmann’s Thrombasthenia arm of ATHN Transcends, and the Site PI/co-investigator on several clinical trials in bleeding and thrombosis. She is a Board member of the Foundation for Women and girls with Blood Disorders and has served on the Medical and Scientific Advisory Committee (MASAC) of the NBDF and the Blood and Blood Products Committee at the FDA. She is actively involved in both patient and provider education through FWGBD and NBDF and has authored or co-authored 88 publications and 10 book chapters. Her clinical interests are in improving care for girls/persons with the propensity to menstruate and all patients with bleeding disorders and her research interests are in global hemostasis assays and their utility in the diagnosis and management of bleeding and thrombotic disorders.
Education & Training
- Children's Hospital of MichiganFellowship, Pediatric Hematology/Oncology, 2001 - 2005
- Henry Ford Hospital/Wayne State UniversityResidency, Pediatrics, 1994 - 1997
- Kempegowda Institute of Medical ScienceClass of 1992
Certifications & Licensure
- MI State Medical License 1997 - 2028
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Top Doc Hour Magazine, 2019-2024
- America’s best physician National Consumer Advisory Board, 2019-2023
- Super Doctor SuperDoctors.com
Clinical Trials
- Personalized Prediction of Tolerance and Immunogenicity in Hemophilia Start of enrollment: 2012 Jun 01
- Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis Start of enrollment: 2023 Aug 16
- SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors Start of enrollment: 2021 Jun 28
Publications & Presentations
PubMed
- A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.Marcio A Almeida, Vincent P Diego, Kevin R Viel, Bernadette W Luu, Karin Haack
Genes and Immunity. 2025-06-01 - Bone Health Screening in Persons With Bleeding Disorders: A Survey of United States Haemophilia Treatment Centres.Divyaswathi Citla-Sridhar, Sanjay Ahuja, Robert Sidonio, Meera Chitlur, Anjali Sharathkumar
Haemophilia. 2025-05-01 - Navigating coagulation: Key markers in the first 24 hours of pediatric ECMO.Jan V Stevens, Katherine Regling, Elika Ridelman, Meera Chitlur, Michelle Veenstra
Perfusion. 2025-04-14
Abstracts/Posters
- On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies (Inhibitors) Directed Against Therapeuti...Meera B. Chitlur, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- An Update on rFVIIa Use in Females with Rare Bleeding Disorders61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Genetics of Factor VIII Inhibitor Development in Hemophilia Patients: Novel Statistical Approaches in the PATH Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: